Capricor stock falls amid data for duchenne muscular dystrophy study Markets January 25, 2023 [ad_1] gorodenkoff Capricor Therapeutics (NASDAQ:CAPR) reported 18-month outcomes from its ongoing HOPE-2 open label extension (OLE) research in sufferers with…
